Arterial imaging has emerged as an increasingly important component of contemporary cardiovascular prevention strategies, enabling direct assessment of subclinical atherosclerosis and refining atherosclerotic cardiovascular disease (ASCVD) risk beyond traditional risk models. Recent dyslipidemia guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) are fundamentally ASCVD risk-based, with imaging incorporated as a complementary tool to refine treatment decisions [1,2].
